公开(公告)号：US20040254190A1

公开(公告)日：2004-12-16

申请号：US10825008

申请日：2004-04-14

Applicant: Pfizer Inc

Inventor： Spiros Liras

IPC: A61K031/52 ,  A61K031/506 ,  A61K031/502 ,  A61K031/501 ,  A61K031/497

CPC classification number: C07D451/02

Abstract: The present invention relates to compounds of the formula I, 1 wherein R1, R2, and R3 are defined as in the specification, pharmaceutical compositions containing such compounds, and the use of such compounds to treat neurological and gastrointestinal disorders.

Abstract translation: 本发明涉及式I化合物，其中R 1，R 2和R 3如说明书中所定义，含有这些化合物的药物组合物，以及这些化合物用于治疗神经系统和 胃肠道疾病。

公开(公告)号：US20040248908A1

公开(公告)日：2004-12-09

申请号：US10677683

申请日：2003-10-02

Applicant: Aventis Pharmaceuticals Inc.

Inventor： David Borcherding ,  Jennifer A. Dumont ,  Norton P. Peet ,  Paul S. Wright

IPC: A61K031/52 ,  C07D473/12

CPC classification number: C07D473/16

Abstract: The present invention is directed to acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines of the formula 1 where Z is selected from the group consisting of nullS(O)2null, and nullC(O)null.

Abstract translation: 本发明涉及下式的6,9-二取代的2-（反-1,4-二氨基环己基） - 嘌呤的酰基和磺酰基衍生物，其中Z选自-S（O）2 - ，和 -C（O） - 。

公开(公告)号：US20040235867A1

公开(公告)日：2004-11-25

申请号：US10484986

申请日：2004-01-23

Inventor： Mark T. Bilodeau ,  Peter J. Manley ,  George D. Hartman

IPC: C07D471/02 ,  C07D491/02 ,  A61K031/519 ,  A61K031/52

CPC classification number: C07D495/04 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04

Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

公开(公告)号：US20040209889A1

公开(公告)日：2004-10-21

申请号：US10470561

申请日：2003-07-29

Inventor： Christopher F Claiborne ,  David A Claremon ,  Brian E Libby ,  John W Butcher ,  John A McCauley ,  Nigel J Liverton ,  Peter M Munson ,  Kevin T Nguyen ,  Brian Phillips ,  Wayne Thompson

IPC: A61K031/525 ,  A61K031/52 ,  A61K031/519 ,  A61K031/517 ,  A61K031/4709 ,  A61K031/4745

CPC classification number: C07D409/14 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  C07D451/02 ,  C07D471/04 ,  C07D473/16 ,  C07D473/34 ,  C07D475/08

Abstract: Compounds represented by Formula (I): (I)or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain. 1

Abstract translation: 由式（I）表示的化合物：（I）或其药学上可接受的盐作为可用于缓解疼痛的NMDA NR2B拮抗剂是有效的。

公开(公告)号：US20040204428A1

公开(公告)日：2004-10-14

申请号：US10484491

申请日：2004-01-22

Inventor： Tarzia Giorgio ,  Giovanni Piersanti ,  Luca Giorgi

IPC: C07D473/14 ,  C07D471/02 ,  A61K031/52

CPC classification number: C07D471/04 ,  A61K31/198 ,  A61K31/435 ,  A61K31/52 ,  C07D473/34 ,  A61K2300/00

Abstract: 1 Compounds of formula (I) wherein the groups are as defined in the description, said compounds being antagonists of the adenosine A2a receptor and useful as medicaments, in particular for the treatment of Parkinson's disease are disclosed.

Abstract translation: 公开了式（I）化合物，其中基团如说明书中所定义，所述化合物是腺苷A2a受体的拮抗剂，可用作药物，特别是用于治疗帕金森病。

公开(公告)号：US20040204416A1

公开(公告)日：2004-10-14

申请号：US10833714

申请日：2004-04-27

Applicant: Pfizer Inc

Inventor： Brian Thomas O'Neill ,  Jotham Wadsworth Coe ,  Christopher J. O'Donnell

IPC: A61K031/52 ,  A61K031/498 ,  A61K031/519

CPC classification number: C07D471/08

Abstract: The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant null7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant null7 nicotinic receptor agonist.

公开(公告)号：US20040157834A1

公开(公告)日：2004-08-12

申请号：US10774668

申请日：2004-02-09

Applicant: Pfizer Inc

Inventor： Bruce A. Hay ,  Bridget M. Cole ,  Anthony P. Ricketts

IPC: A61K031/5415 ,  A61K031/538 ,  A61K031/53 ,  A61K031/495 ,  A61K031/525 ,  A61K031/52

CPC classification number: C07K5/06139 ,  A61K38/00 ,  C07K5/06191

Abstract: Compounds according to the formula A-Z-W as herein described, wherein A is selected from the groups consisting of: Anull-(CH2)nnull, Anull-(CH2)nSO2null, and Anull-(CH2)nCOnull, where n is 0 to 4; and Anull is selected from (a) (C6-C10)aryl-, or (b) (C1-C9)heteroaryl-; which groups may be optionally substituted; and pharmaceutically acceptable salts, solvates or hydrates thereof; pharmaceutical compositions thereof; and methods useful to facilitate secretion of growth hormone(GH) in mammals.

Abstract translation: 根据本文所述的式AZW的化合物，其中A选自：A' - （CH 2）n - ，A' - （CH 2）n SO 2 - 和A' - （CH 2）n CO-，其中n 为0〜4; 并且A =选自（a）（C 6 -C 10）芳基 - 或（b）（C 1 -C 9）杂芳基 - ; 哪些基团可以任选被取代; 及其药学上可接受的盐，溶剂合物或水合物; 其药物组合物; 以及有助于哺乳动物分泌生长激素（GH）的方法。

公开(公告)号：US20040152659A1

公开(公告)日：2004-08-05

申请号：US10716865

申请日：2003-11-20

Applicant: Fujisawa Pharmaceutical Co. Ltd.

Inventor： Nobuya Matsuoka ,  Akira Moriguchi ,  Miho Tada ,  Takuma Mihara

IPC: A61K031/7076 ,  A61K031/52

CPC classification number: A61K31/501 ,  A61K31/00 ,  A61K31/437 ,  A61K31/4985 ,  A61K31/50 ,  A61K31/52 ,  A61K31/522 ,  C07D471/04 ,  A61K2300/00

Abstract: Preventives and/or remedies for Parkinson's disease and symptoms associating therewith such as anxiety, depression and/or memory disorder which contain as the active ingredient an adenosine A1A2a receptor dual antagonist or salts thereof.

Abstract translation: 帕金森氏症的预防和/或补救措施以及与其相关的症状，例如焦虑，抑郁和/或记忆障碍，其包含作为活性成分的腺苷A1A2a受体双重拮抗剂或其盐。

公开(公告)号：US20040116448A1

公开(公告)日：2004-06-17

申请号：US10474318

申请日：2004-01-29

Inventor： Hans-Gunther Schmalz ,  Aram Prokop ,  Thomas P. Wieder ,  Peter T. Daniel

IPC: A61K031/52 ,  A61K031/513

CPC classification number: A61K31/506 ,  A61K31/295 ,  Y02A50/411

Abstract: The invention relates to medicaments and compounds for the treatment of diseases caused by highly proliferating cells, such as tumor cells, especially blasts of children suffering from acute leukemia. The invention also relates to the preparation of the corresponding medicaments and compounds.

Abstract translation: 本发明涉及用于治疗由高增殖细胞引起的疾病的药物和化合物，例如肿瘤细胞，特别是患有急性白血病的儿童的母细胞。 本发明还涉及相应的药物和化合物的制备。

公开(公告)号：US20040110774A1

公开(公告)日：2004-06-10

申请号：US10713860

申请日：2003-11-17

Inventor： Constance Neely Wilson

IPC: A61K039/395 ,  A61K031/52

CPC classification number: C07K16/28 ,  A61K31/52 ,  A61K45/06 ,  A61K2039/505 ,  A61K2300/00

Abstract: A1 adenosine receptor antagonists and P2X purinoceptor antagonists are useful in the treatments of disorders of the immune system, which include HIV infection, AIDS, and adenosine deaminase deficiency-dependent severe immunodeficiency disease (ADA SCID).

Abstract translation: A1腺苷受体拮抗剂和P2X嘌呤受体拮抗剂可用于治疗免疫系统疾病，包括HIV感染，AIDS和腺苷脱氨酶缺乏依赖性严重免疫缺陷病（ADA SCID）。